Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases utilizing its proprietary bile acid chemistry. Co.'s marketed product, Ocaliva® (obeticholic acid or OCA), is an farnesoid X receptor agonist approved in the U.S., the European Union and several other jurisdictions for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. In addition, Co. is developing OCA for additional indications, including nonalcoholic steatohepatitis. We show 48 historical shares outstanding datapoints in our ICPT shares outstanding history coverage, used to compute ICPT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ICPT market cap history over the course of time is important for investors
interested in comparing ICPT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ICPT versus a peer is one thing; comparing
ICPT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ICPT can fluctuate over the course of history.
With this page we aim to empower investors researching ICPT by allowing them to research the ICPT market cap history. |
Free ICPT Email Alerts:
Video: The Importance of Market Cap
